Afamitresgene Autoleucel in MAGE-A4-Positive Advanced Synovial Sarcomas: Clinical Efficacy, Mechanisms of Action, Challenges, and Future Directions

Abstract Afamitresgene autoleucel (afami-cel, Tecelra) marks a significant advancement in the therapy for advanced synovial sarcomas expressing HLA-A*02 and MAGE-A4, having received Food and Drug Administration authorization in 2024. This autologous T-cell therapy utilizes lentiviral SPEAR T-cell receptor technology to precisely target MAGE-A4, a cancer-testis antigen found in 33 to 70% of synovial sarcoma cases. Clinical results from the SPEARHEAD-1 trials show a standardized response rate of 39 to 43% and a median response duration of 6 and 11.6 months. However, obstacles like HLA (human leukocyte antigen)-related constraints, cytopenia, and extended production durations continue to exist. Upcoming initiatives ought to focus on choosing patients according to H-score and tumor load to improve the treatment's efficacy for this aggressive type of soft tissue sarcoma.

Authors

Institutions

Publication Details

Journal
Indian Journal of Medical and Paediatric Oncology
Published
2026-11-12
DOI
https://doi.org/10.1055/s-0046-1829667
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Afamitresgene Autoleucel in MAGE-A4-Positive Advanced Synovial Sarcomas: Clinical Efficacy, Mechanisms of Action, Challenges, and Future Directions

Dinesh Kumar Upadhyay, Diya Rajput, Sneha Singh, Bhavya Dudeja
Indian Journal of Medical and Paediatric Oncology
CAR-T cell therapy research
article

Afamitresgene Autoleucel in MAGE-A4-Positive Advanced Synovial Sarcomas: Clinical Efficacy, Mechanisms of Action, Challenges, and Future Directions

Dinesh Kumar Upadhyay, Diya Rajput, Sneha Singh, Bhavya Dudeja
article en

Abstract

Abstract Afamitresgene autoleucel (afami-cel, Tecelra) marks a significant advancement in the therapy for advanced synovial sarcomas expressing HLA-A*02 and MAGE-A4, having received Food and Drug Administration authorization in 2024. This autologous T-cell therapy utilizes lentiviral SPEAR T-cell receptor technology to precisely target MAGE-A4, a cancer-testis antigen found in 33 to 70% of synovial sarcoma cases. Clinical results from the SPEARHEAD-1 trials show a standardized response rate of 39 to 43% and a median response duration of 6 and 11.6 months. However, obstacles like HLA (human leukocyte antigen)-related constraints, cytopenia, and extended production durations continue to exist. Upcoming initiatives ought to focus on choosing patients according to H-score and tumor load to improve the treatment's efficacy for this aggressive type of soft tissue sarcoma.

Indian Journal of Medical and Paediatric Oncology
Jaipur National University (IN)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon